Madrigal Pharmaceuticals MDGL currently markets Rezdiffra (resmetirom), as the first and only FDA-approved therapy for the treatment of adult patients with noncirrhotic MASH with moderate to ...

Shares of Akero Therapeutics AKRO skyrocketed 105.7% in a week after the company announced initial positive top line 96-week ...

Learn how managing high blood pressure and high cholesterol keeps your heart health in check and helps prevent liver issues such as MASH.

but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. The Massachusetts company has reported the results of the phase 3 MAESTRO ...

Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist. Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis (NASH).

Rezdiffra received U.S. FDA approval as the first and only treatment ... Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target ...

Analysts have suggested that the benefit of semaglutide is similar to that seen with Madrigal Pharma's Rezdiffra (resmetirom), currently the only FDA-approved therapy for MASH, which is also known ...